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Summary
Background We hypothesize that perinatal exposures, in particular the human micro-
biome and maternal nutrition during pregnancy, interact with the genetic predisposition
to cause an abnormal immune modulation in early life towards a trajectory to chronic
inflammatory diseases such as asthma and others.
Objective The aim of this study is to explore these interactions by conducting a longitudinal
study in anunselected cohort of pregnantwomen and their offspringwith emphasis on deep
clinical phenotyping, exposure assessment, and biobanking. Exposure assessments focus on the
humanmicrobiome. Nutritional intervention during pregnancy in randomized controlled trials
are included in the study to prevent disease and to be able to establish causal relationships.
Methods Pregnant women from eastern Denmark were invited during 2008–2010 to a
novel unselected ‘COPSAC2010’ cohort. The women visited the clinic during pregnancy
weeks 24 and 36. Their children were followed at the clinic with deep phenotyping and
collection of biological samples at nine regular visits until the age of 3 and at acute
symptoms. Randomized controlled trials of high-dose vitamin D and fish oil supplements
were conducted during pregnancy, and a trial of azithromycin for acute lung symptoms
was conducted in the children with recurrent wheeze.
Results Seven hundred and thirty-eight mothers were recruited from week 24 of gesta-
tion, and 700 of their children were included in the birth cohort. The cohort has an over-
representation of atopic parents. The participant satisfaction was high and the adherence
equally high with 685 children (98%) attending the 1 year clinic visit and 667 children
(95%) attending the 2 year clinic visit.
Conclusions The COPSAC2010 birth cohort study provides longitudinal clinical follow-up
with highly specific end-points, exposure assessments, and biobanking. The cohort has a
high adherence rate promising strong data to elucidate the interaction between genomics
and the exposome in perinatal life leading to lifestyle-related chronic inflammatory disor-
ders such as asthma.
Keywords Asthma, eczema, allergy, child, birth cohort, microbiome, vitamin D, fish oil,
randomized clinical trial
Submitted 19 November 2012; revised 19 July 2013; accepted 4 September 2013
Background
Asthma, eczema, and allergy are the most common
chronic diseases in childhood and the major cause for
healthcare utilization [1]. These diseases are rarely life-
threatening, but severely affect the quality of life of
children and their families, in particular families with
young children.
The prevalence of childhood asthma, eczema, and
allergy has increased several fold in recent decades in
westernized cultures, suggesting a strong influence of
environmental factors on disease expression [2, 3]. Dis-
eases with such dramatic increase despite a generally
improved welfare and health care represent a significant
societal and scientific challenge. With a stable genetic
pool, the changing geographical and temporal inci-
dences offer evidence of important, yet unknown, life-
style changes causing a new category of welfare
diseases. Particularly, environmental exposures in pre-
natal and perinatal life, including the early microbiome
[4, 5] and maternal vitamin D [6] and fish oil [7, 8]
intake during pregnancy, have been hypothesized to
affect the risk of asthma, eczema, and allergy. Risk
factors and pathways seem to be shared with other
chronic inflammatory diseases later in life [8] meaning
that understanding of the mechanisms causing asthma,
eczema and allergy may have implications for a wider
range of lifestyle related inflammatory disorders.
The mission of the Copenhagen Prospective Studies on
Asthma in Childhood (COPSAC) is to develop new knowl-
edge on the inception of asthma, allergy, and eczema in
order to provide a basis for primary and secondary pre-
ventive measures, novel diagnostic tests, and therapeu-
tics for these chronic diseases. COPSAC is fundamentally
a prospective clinical study of pregnancy cohorts follow-
ing the children with an intense focus on longitudinal
deep phenotyping in disease and health together with
genotyping and objective assessments of the exposome.
The first COPSAC birth cohort was built around year
2000 (COPSAC2000) of 411 children of mothers with a
history of asthma [9]. This at-risk cohort has generated
substantial new insights into the origins of asthma,
eczema, and allergy. Ten years later, COPSAC has built
a second birth cohort (COPSAC2010) on the routines and
experiences of the first COPSAC2000 birth cohort. The
aim is to replicate and explore key findings from COP-
SAC2000 in an unselected population. Randomized con-
trolled trials of high-dose vitamin D and fish oil
supplements were conducted during pregnancy, and a
trial of azithromycin for acute lung symptoms was con-
ducted in the children with early asthma symptoms.
These interventions were included to prevent and treat
disease and to be able to establish causal relationships
behind previously observed associations. The main
hypotheses are as follows:
• Chronic inflammatory disorders like asthma are pro-
grammed in the perinatal life as the results of complex
gene–environment interactions.
• The early human microbiome is an important envi-
ronmental exposure, where an unbalanced composi-
tion may cause deregulation of the immature
immune system leading to a trajectory towards
chronic inflammatory diseases such as asthma.
• Maternal diet during pregnancy influence maturation
and regulation of neonatal immune responses and
provide an opportunity for preventive supplementa-
tion with vitamin D and n-3 long-chain polyunsatu-
rated fatty acids (n-3 LCPUFA) in pregnancy.
• Asthma, eczema, and allergies represent several spe-
cific endotypes, each associated with divergent
underlying molecular mechanisms, distinct clinical
features, and individual treatment responses. Identi-
fying these endotypes is essential for establishing
effective preventive measures and determining
appropriate individualized treatment.
This article describes the recruitment, baseline, clini-
cal study programme, and the standard operating pro-
cedures built for the COPSAC2010 birth cohort. The aim
is to share methods and hypotheses of the COPSAC
resource that will generate important scientific discov-
eries in the future and to invite international collabora-
tors to explore this vast biobank and metadata.
Materials and methods
COPSAC2010 pregnancy cohort
Recruitment. The study catchment area was Zealand, an
island in the eastern part of Denmark, including the capi-
tal Copenhagen. Pregnant women were recruited by a
monthly surveillance of reimbursement to general practi-
tioners for the mandatory pregnancy visit. They received
an invitation by posted mail to contact the clinic during
2008–2010. Exclusion criteria were gestational age above
week 26; daily intake of more than 600 IU vitamin D dur-
ing pregnancy; or having any endocrine, heart, or kidney
disorders. Women who contacted the COPSAC clinic by
phone received detailed verbal information. Those who
were still interested and qualifying for the study received
comprehensive study information by posted mail. Finally,
the women attended the clinical research unit within
pregnancy weeks 22–26 for a visit in the research clinic-
with detailed information and enrolment into the preg-
nancy cohort.
Power calculation. The cohort was powered for replica-
tion of the association between neonatal airway coloni-
zation and early asthma symptoms as discovered in
COPSAC2000 [4]. The main outcome was ‘recurrent
wheeze’, based upon an algorithm of recurrent trouble-
some lung symptoms as previously described [10]. Power
calculations were based on survival analysis (log-rank
test). Based on the findings from COPSAC2000, we
assumed that 12% of children would develop ‘recurrent
wheeze’ in the first 3 years of life (16.5% in the COP-
SAC2000 high-risk cohort). Furthermore, the following
were assumed: the prevalence of colonization in infancy
to be 20% (21% in COPSAC2000); a hazard ratio of 2 asso-
ciated with colonization (2.40 in COPSAC2000); an expo-
nential survival curve; and a dropout rate of 5%
© 2013 John Wiley & Sons Ltd, Clinical & Experimental Allergy, 43 : 1384–1394
The unselected COPSAC2010 birth cohort 1385
of recruited pregnant women and of further 15% of
children by age 3 years. With a significance level of 0.05
and a power of 80%, the required sample size would be
660 recruited pregnant women. Statistical power for the
randomized trials was calculated based on the available
numbers. Six hundred and ninety-eight newborns were
included in the fish oil study and 587 in the vitamin D
study. With an assumed hazard ratio of 0.5 in the treat-
ment arms and expected frequency of ‘recurrent wheeze’
of 12% in the control arm, this resulted in a power of
73% for detection of a statistically significant difference
with a significance level of 0.05. Statistical power in the
vitamin D study following similar calculations was 65%.
Selection analysis. Characteristics of the women not
included in the pregnancy cohort were analysed from
letters sent to 1000 women, who had not responded to
the primary invitation, inviting them to answer a num-
ber of general health questions. Reminder letters were
sent on two occasions to non-responders.
COPSAC2010 birth cohort
Neonates born to the women from the COPSAC2010
pregnancy cohort were included in the COPSAC2010
birth cohort.
Scheduled visits were planned at 1 week, 1, 3, 6, 12,
18, 24, 30, and 36 months, and regularly thereafter
until age 7.
Acute visits were arranged whenever parents consid-
ered the need for medical attention for significant trou-
blesome lung symptoms or at the onset or exacerbation
of eczema. Asthma, eczema, allergic rhinitis and respira-
tory infections were diagnosed and treated by the doc-
tors in the research clinic according to predefined
algorithms (detailed in the Supporting information).
Database. All information was obtained by personal
interview at clinical visits by medical doctors (MDs)
and research assistants both with paediatric training.
Medical, familial, environmental, and socio-economic
histories were assessed by predefined questions and
closed response categories and entered online into a
dedicated database running an audit trail (Oracle data-
base on a Novel SQL server). Objective information and
measurements were entered into the database, subse-
quently double-checked against source data, and finally
locked for further editing. Quality assurance followed
‘Good Clinical Practice’ guidelines (detailed in the Sup-
porting information).
Standard operating procedures (SOPs) were predefined
for all study and database registration procedures similar
to those used in the ongoing at-risk COPSAC2000 birth
cohort study (see Supporting information) and were
available online and in binders in every clinic room.
Participant communication. Telephone calls, posted
mails, emails, text messages, and Internet survey (www.
esurveyspro.com) were used to keep a close and contin-
uing communication with the participating families
between the visits.
Nested, blinded, controlled, randomized clinical trials
Vitamin D supplement during third pregnancy trimes-
ter. The pregnant women were randomized 1 : 1 to a
daily dose of 2400 IU cholecalciferol D3 daily supple-
ment or matching placebo (Camette, Denmark A/S) from
pregnancy week 24 to 1 week after delivery. All partici-
pants were instructed to continue supplementation of
400 IU cholecalciferol D3 currently recommended by the
Danish National Board of Health; that is, daily doses
were 400 IU vs. 2800 IU. Serum vitamin D level was
assessed at the time of randomization and at completion
allowing for stratification of habitual vitamin D intake
and assessment of adherence to the treatment plan.
Counting returned capsules complemented assessment of
compliance. The primary end-point is the development of
‘recurrent wheeze’, based upon an algorithm of episodes
of troublesome lung symptoms, and will be analysed
when all the participating children reach 3 years of age.
Fish oil supplement during third pregnancy trimes-
ter. From pregancy week 24 to 1 week after delivery,
the pregnant women were randomized 1 : 1 to daily
fish oil supplement (four 1-g capsules (Incromega
TG33/22) supplying a total of 2400 mg/day of n-3
LCPUFA; 1320 mg/day eicosapentaenoic acid (EPA),
and 880 mg/day docosahexaenoic acid (DHA) contrib-
uting to an estimated 10-fold increase relative to the
normal daily intake of n-3 LCPUFA or a matching pla-
cebo (four 1-g capsules of olive oil (Pharmatech A/S,
Norway) containing 72% n-9 oleic acid and 12% n-6
linoleic acid, which contributes an estimated 3% of
normal daily intake of PUFA. Whole-blood PUFA levels
were assessed at the time of randomization and at com-
pletion allowing for stratification of habitual n-3
LCPUFA intake and assessment of adherence to the
treatment plan. Compliance was assessed by counting
returned capsules. The primary end-point is the devel-
opment of ‘recurrent wheeze’, based upon an algorithm
of episodes of troublesome lung symptoms and will be
analysed when all participating children reach 3 years
of age.
Azithromycin treatment of acute severe episodes of
troublesome lung symptoms. The children aged
12–36 months with recurrent episodes of troublesome
lung symptoms lasting at least 3 days were offered par-
ticipation in a double-blinded, randomized, placebo-
controlled treatment with azithromycin or placebo at
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acute episodes of troublesome lung symptoms. Children
were recruited from the main cohort study if they had
recurrent ’wheezy episodes’ (five episodes of three con-
secutive days of troublesome lung symptoms within a
period of 6 months or 4 weeks of continuous trouble-
some lung symptoms or acute severe asthma). At every
subsequent episode, treatment was administered at acute
clinical visits, after excluding suspected pneumonia (tac-
hypnoea, RF ≥50; fever ≥39°C; CRP ≥50). The study was
designed as a double-blind, placebo-controlled, random-
ized, cross-over comparison of azithromycin in a dose
of 10 mg/kg/day (TEVA, Kgs. Lyngby, Denmark A/S) for
3 days or matching placebo (the Pharmacy of Glostrup,
Copenhagen). Randomization of the trials was performed
at the Pharmacy of Glostrup, Copenhagen, and copies of
the randomization code were kept in sealed envelope at
the research site as well as at the pharmacy. The primary
end-points are symptom burden and duration of the
asthmatic episode after randomization and will be anal-
ysed when a total of 250 treatments have been com-
pleted or all children turned 3 years of age.
Figure S9 schematically shows the relationship
between the trials on nutritional intervention during
pregnancy and the trial on azithromycin.
Influenza A H1N1v vaccination. During the H1N1v
pandemic winter 2009–2010, the women were invited
from gestational week 20 until 8 months after birth to
a phase IV randomized, participant-blinded comparison
of monovalent influenza A/California/2009 (H1N1v)
surface antigen vaccine (Focetria, Novartis Vaccines
and Diagnostics GmbH, Marburg, Germany) in both
MF59-adjuvanted and non-adjuvanted forms [11]. The
study consisted of four groups: pregnant women
receiving: (1) 7.5 µg H1N1pnd09 antigen with a full
complement of MF59 adjuvant (P7.5 µg); (2) 3.75 µg
antigen, with half the usual content of MF59
(P3.75 µg); (3) 15 µg antigen, unadjuvanted vaccine
(P15 µg); and (4) non-pregnant women receiving
7.5 µg antigen with full MF59-adjuvanted vaccine
(NP7.5 µg). After recruitment, the pregnant women
were randomized by a computer-generated permuted
block randomization table, in blocks of 45 women with
allocation rate of 1 : 1 : 1. The P3.75 µg group was
closed after 4 months due to low recruitment rate.
Clinical assessments
Daily diary cards were used from birth to monitor sig-
nificant troublesome lung symptoms as previously ana-
lysed in detail [12] including components of cough,
wheeze, and dyspnoea, and use of b2-agonists, inhaled
corticosteroids, and montelukast. Skin symptoms were
monitored as active eczema and use of topical steroids.
In addition, the diary cards monitored infections, cate-
gorized into common cold, pneumonia, pharyngitis, oti-
tis, fever, gastrointestinal infection, and absence from
day care institution because of illness (Figure S1). The
diary cards were reviewed with the family by the
research MD at each visit to validate symptom defini-
tions. All information were subsequently entered into
the online database and double-checked.
Physical examination was performed by the research
MD at all scheduled and acute visits, including lung
and heart stethoscopy and examination of skin [13, 15],
ear, nose, and throat.
CRP measurement was performed at acute visits or
when needed using QuickRead 101 (QuickRead Instru-
ment, Orion Diagnostica, Espoo, Finland).
Tympanometric evaluation of the middle ear pressure
was performed at yearly visits or when needed (MT10,
Interacoustics, Denmark) on both ears.
Spontaneous physical activity was assessed by age
2 years using an omnidirectional accelerometer worn on
the ankle for 2 weeks as previously described [16, 17].
Blood pressure was assessed yearly from age 3 years
(Welch Allyn Connex: ProBP 3400).
Lung function by multiple-breath washout (EcoMed-
ics: Exhalyzer D) was assessed from the age of
3 years.
Airway resistance was measured from 3 years of age
by whole-body plethysmography (Master Screen Body;
Erich Jaeger GmbH; W€urzburg, Germany) [18, 19].
Airflow was measured by spirometry (Vitalograph:
Spirotrac II) before and after inhalation of a standard
dose of b2-agonist from age 5 years.
Fractional nitric oxide (FeNO) was measured using an
Aerocrine NO system (CLG77AM chemiluminescence
analyzer from Ecophysics AG, Duernten, Switzerland)
and assessed from age 5 years.
Anthropometrics
Gestational age and fetal biometrics were determined
by an ultrasound nuchal translucency scan in week
13 of the pregnancy (biparietal diameter and occipito-
frontal diameter, abdominal circumference, length of
femur, and fetal weight estimated by the Hadlock equa-
tion for fetuses <2500 g) [20].
Length was measured at every visit until age
24 months by the infantometer, Kiddimetre (Raven
Equipment Limited, Essex England).
Height was measured at every visit from age
24 months (i.e. overlapping with length at age
24 months) by Harpenden stadiometer (Holtain Ltd,
Crymych, Dyfed, Wales).
Parental height was measured at recruitment to the
study with Harpenden stadiometer.
Weight was measured at every visit using calibrated
digital weight scales.
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Head circumference was measured three times at each
visit to the closest millimetre at the frontal and occipi-
tal protuberance positions.
Abdominal circumference was measured three times
at each visit at the level of the umbilicus, in the hori-
zontal parallax.
Whole-body dual-energy X-ray absorptiometry
(DXA, GE Healthcare, Fairfield, CT, USA) was measured
at age 3 years for detailed body composition.
Motor and cognitive development
Milestones of motor development were monitored pro-
spectively by the parents using a registration form
based on The Denver Development Index and WHO
milestones registration [21, 22].
Language development was assessed at 12 and
24 months of age by a web-based parent report instru-
ment (MacArthur CDI form) translated into Danish [23].
Cognitive development was assessed at 30 months
using the cognitive part of Bayley Scales of Infant and
Toddler Development, third edition [24]. The tests were
performed by trained examiners, and all sessions were
video recorded allowing reviewing by a single observer.
Immune function
Mucosal lining fluids were sampled from the upper air-
ways at 1 and 24 months of age as well as at all acute
airway visits for assessment of cytokines and chemo-
kines as previously described [25, 27].
At 18-months, whole blood samples were stimulated
with Toll-like receptor (TLR) ligands, cell type-specific
ligands, and a NLRP3 inflammasome ligand. Whole-
blood pheno-typing by flow cytometry was performed at
18 months and in a random subset of cord blood samples.
Skin prick tests with milk, egg, dog, and cat extracts
were performed at 6 and 18 months, using standard
extracts from ALK-ABELLO with both a positive control
and a negative control.
Specific IgE was determined at 6 and 18 months by
ImmunoCAP (Pharmacia Diagnostics AB, Uppsala, Swe-
den) against 15 common inhalant and food allergens
(cat, dog, horse, birch, timothy grass, mugwort, house
dust mites, moulds, hen’s egg, cow’s milk, fish, wheat,
peanut, soybean, and shrimp).
Genomics
Deoxyribonucleic acid was purified from peripheral
blood cell fraction from plasma of the infant collected
at 6 months and from both parents at recruitment and
stored at 80°C.
Genome-wide genotyping was performed using the
Illumina OmniExpress and Exome beadchip and
imputed using both the Hapmap and 1000 genomes ref-
erence populations [28, 29].
RNA was stabilized in the blood sample collected at
18 months and stored at 80°C.
Biobanking
Cord blood was collected by needle puncture from the
umbilical cord immediately after birth (collected by
midwives) and transported to the laboratory by courier,
where cells, plasma, and serum were separated and
stored.
Neonatal dried blood spots were sampled as part of
the neonatal screening programme and stored in the
Danish Neonatal Screening Biobank for further analy-
ses of metabonomics, epigenetic alterations [30] and
cytokine levels [31].
Exhaled volatile organic compounds (VOCs) were
assessed at 1 and 18 months of age and at acute visits.
Breath samples collected were analysed by an ‘Electronic
nose’ (Cyranose 320) with a 32-carbon sensor array for
assessment of fingerprints, and specific VOCs were mea-
sured by gas chromatography–mass spectrometry.
Urine was sampled at 1 and 12 months of age and
stored at 80°C for biomarker analyses.
Peripheral blood was collected by 6 and 18 months
of age and stored as plasma and serum and as periph-
eral blood mononuclear cells at 18 months.
Environmental exposures
History of exposures was recorded yearly from clinical
interviews according to predefined categories including
variables on social status (educational and occupational
status of the parents and household income), siblings,
and home environment (e.g. exposure to pets, passive
smoking, and fireplace at home).
Adherence to asthma medication and use of antibiotics
and other medications was verified from the online
national register on medications filed at Danish pharma-
cies.
Hair samples were obtained at 12, 24, and 36 months
for nicotine and cotinine assessment [32].
Dust samples from bedding were collected at
6 months of age by the parents. Settling dust was col-
lected from the child’s bedroom.
Human microbiome
Vaginal swaps were collected at 24 weeks and 36 weeks
of pregnancy. Wet smears and conventional culture for
bacteria were performed, and material was stored for
full sequencing of the microbiome.
Hypopharyngeal aspirates were collected at 1 week,
1 month, and 3 months after birth, and at every acute
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visit with lung symptoms [33, 34]. The samples were
cultured for conventional bacteria and stored for
sequencing of the microbiome.
Nasopharyngeal aspirates were collected at 1 week,
1 month, 3 months, and at every acute visit with lung
symptoms. Samples were stored for analysis of respira-
tory viruses.
Fecal samples were collected at 1 week, 1 month,
and 12 months. The samples were cultured for conven-
tional bacteria and stored for sequencing of the microb-
iome.
Skin swaps were performed at 12 months of age and
again at 36 months from the volar forearm and the
axilla and stored for sequencing of the microbiome.
Diet
Mother’s diet was assessed from a 360-item question-
naire with detailed information on dietary habits for
the first month prior to recruitment [35].
Breast milk samples were obtained from the mother
1 month post-partum. 0.01% 2,6-di-tert-butyl-4-meth-
ylphenol was added to the milk and stored at 80°C
for later fatty acid analysis [36].
Maternal blood fatty acid levels. EDTA blood samples
were collected from the women in pregnancy week
24 and 1 week post-partum, 0.01% 2,6-di-tert-butyl-
4-methylphenol was added, and the sample was stored
at 80°C. Fatty acid analyses were performed within a
year from sampling by gas chromatography [37, 38].
Approvals
The main study protocol was approved by the Ethics
Committee (H-B-2008-093) and the Danish Data Protec-
tion Agency (2008-41-2599).
Vitamin D supplement randomized controlled trial in
pregnant women: Ethics Committee (H-B-2009-014);
Danish Data Protection Agency (2008-41-2599); Eud-
raCT number 2008-007871-26; ClinTrial.gov ID NCT007
98226.
n-3 LCPUFA supplement randomized controlled trial
in pregnant women: Ethics Committee (H-B-2008-093);
Danish Data Protection Agency (2008-41-2599); Clin-
Trial.gov ID NCT00798226.
Azithromycin randomized controlled trial: Ethics
Committee (H-3-2010-065); Danish Data Protection
Agency (2010-41-5023); EudraCT number 2010-
018592-16. ClinTrial.gov ID NCT01233297.
Influenza A H1N1v vaccination randomized
controlled trail: Ethics Committee (H-B-2008-093);
Danish Data Protection Agency (2009-41-4031); Eud-
raCT number 2009-016877-14; ClinTrial.gov ID
NCT01012557.
Results
Pregnancy cohort recruitment
Brief invitations were posted to 54 358 women. 1876
women responded and received further information.
733 women attended the clinical research unit for
extensive information and were all included in the
pregnancy cohort as illustrated in the flow chart of the
study recruitment (Fig. 1). The 733 women participated
during a total of 738 pregnancies as five women partic-
ipated during two pregnancies. Questionnaires were
mailed to 1000 women, who had not responded to the
study invitation, of whom 870 (87%) women responded
to the questionnaire.
Table 1 compares the populations of 690 mothers
participating in the birth cohort with the group of 870
women choosing not to participate. Women who chose
to participate in the cohort were characterized by
higher prevalence of asthma, eczema, and hayfever.
They were more frequently employed as professional
and less frequently unemployed, and had higher income
levels. There were no differences with respect to
tobacco smoking, alcohol intake, pets at home, or mode
of delivery.
738 women included
1876 women (3.5%) 
contacted the COPSAC clinic
54 358 invitations
mailed 
700 children included
(5 pair of twins)
43 withdrawn before birth:
4: Miscarriage
6: Disabling disease
11: Emigration
22: Other reasons
Fig. 1. Flow of subjects from invitation to the first visit to the COP-
SAC clinic.
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Birth cohort
Forty-three children were withdrawn before enrolment
into the birth cohort (Fig. 1; six disabling diseases, four
deaths, 11 emigrations, 22 unspecified reasons). The
birth cohort enrolled a total of 700 newborns at 1 week
of age (born between 3 November 2008 and 17 March
2011), including five pairs of twins and five pairs of
siblings born of a total of 690 mothers (Fig. 1). Baseline
characteristics of the 700 children in the COPSAC2010
birth cohort are presented in Table 2 and compared
with the previous COPSAC2000 birth cohort. The two
cohorts are quite similar (the predefined difference in
asthma risk aside), except for a remarkable reduction in
mothers’ smoking and intake of alcohol during preg-
nancy, and a higher level of education in the recent
COPSAC2010 cohort.
Adherence
The adherence to the study was high with 685 children
(98%) attending the 1 year visit and 667 children (95%)
attending the 2 year visit.
Cohort satisfaction with study participation. Table 3
shows results from the Internet survey of participant’s
satisfaction with the study. The main complaint was
difficult parking access (27%) and, to a lesser extent,
blood sampling in the infants (9%).
Discussion
The aim of COPSAC is to understand the origins of
chronic inflammatory diseases with a primary focus on
asthma, eczema and allergy in young children and to
translate this into improved disease prevention, diagno-
sis, and treatment; to identify endotypes of diseases in
early life from their disease mechanism; and specifically
to understand the impact of the early human microbi-
ome and maternal diet on the early immune matura-
tion, disease development, and the interaction between
the exposures and the genome.
Clinical birth cohorts
Information based on diagnoses and treatments of
young children decided by community doctors and
hospital records is of very low accuracy and precision.
This is partly due to the fact that clinical assessments,
diagnoses, and treatments are more difficult and impre-
cise in young children than later in life. This is of par-
ticular importance in young children with asthma,
eczema, and allergy where there is very little standardi-
zation of diagnoses and treatments in the general med-
ical community both nationally and internationally [1].
Therefore, the COPSAC cohort studies of pregnant
women and their children were planned as longitudinal
clinical monitoring of symptoms, objective end-points,
and environmental exposures at a clinical research site
with a standardized approach to diagnosis and treat-
ment [9]. The deep phenotyping includes prospective
daily symptom characteristics, lung function tests, bio-
markers, and other objective measurements performed
at regular visits to the clinic from birth till adulthood.
Analysis of biomarkers was planned in accordance to
NIH guidelines [39]. COPSAC serves as the de facto pri-
mary health centre for the cohorts of approximately
1100 children with regular and acute visits to the
clinic. The cohorts use the COPSAC research clinic for
all airway- and skin-related diagnoses and treat-
ments, avoiding the inconsistent practice in the com-
munity. This close adherence of the cohort to our
research unit allows us to standardize all procedures
Table 1. Dropout analysis. Results from questionnaires mailed to 1000
women who had received an invitation during pregnancy, but chosen
not to participate in the COPSAC2010 pregnancy cohort, compared
with mothers of children participating in the study. The questionnaire
response rate was 86%.
Non-
participants,
N = 870*
COPSAC2010
N = 690† P-value
Natural birth 82% 78% 0.098
Furred pets in the home 36% 38% 0.458
Smoking during pregnancy,
more than one
cigarette per week
9% 7% 0.256
Alcohol during pregnancy,
more than one unit
per week
2% 2% 0.697
Asthma (self-reported) 11% 30% <0.001
Eczema (self-reported) 12% 21% <0.001
Allergy (self-reported) 27% 34% <0.0001
Hayfever (self-reported) 20% 38% <0.0001
Education level, university
education longer
than 3 years
33% 36% 0.18
Employment 0.006
Unemployed 10% 6% –
Student 8% 8% –
Non-professional 8% 9% –
Professional 73% 78% –
Household income <0.001
Below 400 000 DKK 22% 12% –
400 000 DKK–600 000 DKK 27% 22% –
600 000–800 000 DKK 27% 29% –
Above 800 000 DKK 24% 37% –
*The response rate for the different variables varied from 849 to 870
of 870 non-participants.
†The response rate for the different variables varied from 620 to 690
of 690 participants.
Significant associations (P < 0.05) were marked in bold.
© 2013 John Wiley & Sons Ltd, Clinical & Experimental Allergy, 43 : 1384–1394
1390 H. Bisgaard et al.
including objective assessments, diagnostic criteria, and
medical treatments.
Proposed dietary risk factors, such as vitamin D and
fish oil intake during pregnancy, are likely to be subject
to confounding from lifestyle factors, which can only
partly be controlled for in observational studies. We
therefore chose to study these hypothesized risk factors
in embedded randomized controlled trials to be able to
standardize these possible confounders as well as estab-
lish any causal effects. The choice of applying several
randomized trials in the same cohort carries the risk of
interaction between treatments that must be accounted
for in the statistical analyses. The argument for doing this
is that the applied interventions are environmental fac-
tors that all pregnant women are normally exposed to
and often use as supplementations. Vitamin D and fish oil
levels vary markedly between individuals as a result of
different lifestyles in terms of sun exposure, diet, and
intake of supplements, and antibiotics are commonly
used as part of the treatment of asthma exacerbations [1].
The randomized trials will allow us to assess potential
causal effects and effect modification from these expo-
sures that would otherwise still be present as confound-
ing factors without standardization.
Table 2. Baseline characteristics of the COPSAC2010 cohort and com-
parison with COPSAC2000
Probands COPSAC2010 COPSAC2000
Mothers enrolled, n 738* 452
Number of newborns, n 700† 411‡
Birth cohort
Boys 51.4% 49.4%
Twin pairs 1% 2%
Sibling pairs 1% 2%
Caucasian 96% 97%
Mother’s age at birth,
mean (SD), years
32.2 (4.4) 30.0 (4.5)
Father’s age at birth,
mean (SD), years
34.4 (5.6) 32.0 (5.2)
Season of birth
Winter 31% 23%
Spring 27% 21%
Summer 21% 27%
Fall 21% 29%
Pregnancy and birth
Assisted reproductive technology 10%
Gestational age, mean (SD), weeks 39.9 (1.7) 39.9 (1.6)
Birthweight, mean (SD), kg 3.54 (0.555) 3.52 (0.519)
Birth length, mean (SD), cm 51.9 (2.5) 52.3 (2.3)
Head circumference at 1 week,
mean (SD), cm
35.7 (1.4) 35.2 (1.6)
Apgar at 5 min., mean (SD) 9.9 (0.34) 9.8 (0.6)
Mode of delivery, caesarean
section,
22% 21%
Acute 12% 12%
Elective 9% 9%
Newborns hospitalized in relation to labour
Preterm birth (<36 weeks) 3% Excluded
In need of assisted ventilation 2% Excluded
Other reasons 4% 2%
Mothers hospitalized in
relation to labour
12%
Exposures
Parity
1 46% 46%
2 38% 26%
3 or more 16% 28%
Older children in household
0 43% 64%
1 38% 24%
2 15% 8%
3 or more 4% 3%
Mother smoking during pregnancy 8% 24%
Alcohol use during pregnancy
(any)
14% 26%
Antibiotics during pregnancy (any) 37%
Antibiotics during birth (any) 33%
Furred pets at home (any) 37% 30%
Duration of solely breastfeeding,
mean (SD), days
105 (62) 113 (62)
Duration of breastfeeding,
mean (SD), days
240 (144) 246 (156)
(continued)
Table 2 (continued)
Probands COPSAC2010 COPSAC2000
Socio-economic variables
Household annual income
Index 2010. National average household income for families in 2010: 458 527 DKr
Below 400 000 DKK 10% 21%
400 000–600 000 DKK 24% 31%
600 000–800 000 DKK 29% 30%
Above 800 000 DKK 37% 17%
Mothers with university education
(more than 3 years)
28% 13%
Fathers with university education
(more than 3 years)
28% 17%
Mothers without occupation
(unemployed or student)
13% 19%
Fathers without occupation
(unemployed or student)
8% 7%
Atopic disposition (diagnosed by doctor)
Mothers with asthma 26% 100%
Mothers with allergic rhinitis 30% 73%
Mothers with eczema 27% 46%
Fathers with asthma 21% 15%
Fathers with allergic rhinitis 27% 30%
Fathers with eczema 15% 11%
*Mothers were recruited during 738 unique pregnancies, but these
only represent 733 women as five women participated with more than
one child (five sibling pairs participating in the cohort).
†The response rate for the different variables varied from 680 to 700
of 700 children.
‡The response rate for the different variables varied from 385 to 411
of 411 children.
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We are applying new objective methods of disease
assessment to target and refine our understanding of the
different endotypes. These include breathomics, metabo-
lomics local airway immune profiling, and multiple-
breath washout, all applicable to clinical practice as
non-invasive methods.
We first applied this longitudinal clinical approach in
the COPSAC2000 birth cohort. Records from the family
practitioners were compared with our data from the
COPSAC2000 cohort showing no missing information on
atopic disorders and infections, although some under-
reporting on trauma [40]. Our studies have often
showed strong statistical power compared with larger
study numbers presumable because of the highly spe-
cific end-points and exposure assessments and the
accurate information on time of onset.
Study compliance
The intensive regime with several hour-long visits at the
clinic every 6 months is very resource demanding for the
research unit and certainly for the families often needing
to take days off from work. And yet the adherence is
good with approx. 80% follow-up after 7 years in our
first birth cohort, COPSAC2000. This first birth cohort only
included mothers with a history of asthma that is likely
to have strengthened motivation and adherence. Still, the
early indications from the COPSAC2010 novel unselected
birth cohort are encouraging with a very high adherence
rate of 98% at age 1 year and 95% at age 2 years.
Recruitment bias
All pregnant women attending general practitioners in
our recruitment area covering both urban and rural
areas were targeted for an invitation to participate in
the study. Regular health check during pregnancy with
the general practitioner is free and recommended for
all women, and the invitations were therefore without
bias. Still, with a defined aim to analyse risk of
asthma, eczema, and allergy, we find the expected over-
representation of these diseases compared with non-par-
ticipants. This confirms that it is unlikely that any
cohort study with a disease focus will be truly unse-
lected. The participants differed from non-participants
with respect to socioeconomic factors, including
employment and income level, while there was no
apparent bias with respect to other suspected risk factors
such as the mode of delivery, living with pets, smoking,
or alcohol intake during pregnancy.
Cohort maintenance
In an Internet-based survey, we found a generally very
high level of satisfaction with the visits to the clinic
including access to acute help, level of information,
appreciation from the personal at the clinic, and the
sampling taken from the child (Table 3). In particular,
only 9% were displeased with the repeated blood sam-
plings from the infant.
Ethics
We are cognizant of the need to ensure the highest ethical
standards when involving pregnant women and young
children in research, emphasizing the autonomy and
respect for the decisions of participants. The study con-
forms to the Declaration of Helsinki in its latest version,
and the Danish Ethical Committee and the Danish Data
Protection Agency have approved the projects. The safety
of the randomized control study of two supplements
during pregnancy has been reviewed by the Danish
Table 3. Internet-based survey of COPSAC2010 participants conducted
in the period from 22 June 2011 to 5 January 2012. 618 responders
of 690 study families
Study convenience Unsatisfied Satisfied
Very
satisfied
N
answered
Access to unscheduled
visits
3% 49% 48% 612
Regular examinations
by doctor
1% 38% 61% 618
Information on planned
investigations
1% 32% 67% 618
Burden of
study visits and
procedures
1% 54% 45% 614
Continuity of
research personnel
6% 51% 43% 618
Atmosphere at the
research clinic
0% 18% 82% 615
Waiting time in the
research clinic
0% 34% 66% 613
Parking accessibility 27% 60% 13% 618
Study procedures Unsatisfied Satisfied
Very
satisfied
N
participated
Blood sampling
in parents
1% 37% 62% 609
Blood sampling
in child
9% 43% 48% 565
Mucosal lining
fluid sampling
in child
2% 45% 53% 605
Hypopharyngeal
aspiration
in child
2% 47% 51% 608
VOC sampling in
exhaled air
2% 43% 55% 601
Accelerometer fixed
for 2 weeks
on the ankle of
the child
2% 53% 45% 207
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Medicines Agency and is monitored by the Copenhagen
GCP unit. The persons involved in the study participate
voluntarily and after written informed consent by both
parents. The participating families are informed that the
study is unlikely to benefit their child and that discover-
ies will only benefit future generations. The analyses of
the biobank are anonymized, and the results are not
provided to the families. The participants have the advan-
tage of a consultation by a paediatrician when they have
any symptoms from the airways or skin, which is
expected to facilitate early diagnosis and treatment. Suc-
cessful early diagnosis and effective treatment will reduce
morbidity and therefore improve quality of life.
In the COPSAC2000 birth cohort study, we conducted
semi-structured qualitative interviews with parents and
children to assess ethical questions pertaining to such
comprehensive and invasive clinical research. It was the
consistent conclusion that it is possible to conduct inva-
sive clinical research on infants and young children in a
manner that parents find ethically sound. Altruism was
their primary motivation and secondly the comfort of
close and easy access to paediatricians and other special-
ists [41], while the children themselves after 7 years of
participation emphasized the friendship they had built
with the COPSAC study group [42]. In this novel COP-
SAC2010 cohort, we used Internet-based survey tools to
ask the parents anonymously about the motivation for
participation (Table 3). Again altruism was the main rea-
son given by 65% of the cohort, a particular interest in
asthma, eczema, and allergy was the second most com-
mon reason given by 21% of the cohort.
Conclusion
Preventive measures against asthma, eczema, and allergy
have largely failed due to our lack of understanding
of the disease origins. The COPSAC studies apply a
translational clinical research approach based on
long-term studies of birth cohorts with deep phenotyping
and exposure assessment, genotyping, and sequencing of
the microbiome. Combined with randomized controlled
trials, insight into the genetic regulation of basic biologi-
cal processes, and state-of-the-art systems biology meth-
ods, this approach holds the promise to improve our
understanding of the processes causing disease in indi-
vidual patients and the interaction between heredity and
environment. Identification of the environmental factors
that promote or protect against future disease raises real-
istic hope of prevention. This may provide the basis for
the development of novel diagnostic tests, identification
of molecular drug targets, and the possibility of individu-
alized treatment. This research programme will eventu-
ally have significant effect on public health, as these
diseases affect approximately one-fifth to one-third of
all families in westernized countries and may represent
communality with other chronic inflammatory diseases
developing later in life.
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